Editorial Policy

Our rule: We separate established facts, active research, and commercial claims. Approval status comes from official regulatory databases. Study descriptions identify population and phase. Affiliate relationships are disclosed near links. We do not publish generic dosing, reconstitution, or injection protocols for unapproved products.

How topics are selected

We prioritize questions people are already asking where online answers commonly blur approval status, overstate early evidence, or misuse laboratory quality terms.

Source hierarchy

Primary sources receive priority: FDA pages and labeling, ClinicalTrials.gov records, peer-reviewed trials, and official guidance. Secondary summaries may help explain context but do not override primary records.

Commercial independence

Future affiliate relationships may influence which products are linked, but they do not change status labels or evidence summaries. Payment does not convert a research compound into an approved medicine.

Corrections

Material corrections are made promptly and preserved in WordPress revision history. Contact the editorial team with the page URL, disputed statement, and supporting primary source.

Prohibited editorial shortcuts

We do not copy seller descriptions, create anonymous medical-review claims, use AI-generated citations without opening the source, or convert trial protocols into consumer instructions.

Affiliate link rules

Links remain disabled until a separate money site is ready and reviewed. When activated, disclosures appear near recommendations, outbound domains are allowlisted, and links use sponsored attributes.

Use of automation

Automation may assist research organization and drafting, but a human editor is responsible for source verification, status labeling, internal linking, and final publication.

Update triggers

Pages should be reviewed after FDA approvals, safety communications, warning letters, major trial results, labeling changes, or meaningful corrections.